TABLE 1.
Clinical data from control and ulcerative colitis (UC) patients.
| Sample | Sex | Age | Medication | Histology | Location | Arpin | ArpC5 |
| Ctrl 1 | F | 60 | None | Colon ascendens carcinoma | Colon ascendens | 0.9613 | 1.0094 |
| Ctrl 2 | M | 82 | None | Colon ascendens carcinoma | Colon ascendens | 1.3864 | 0.9304 |
| Ctrl 3 | M | 49 | None | High-grade IEN cecum | Colon ascendens | 1.0732 | 0.8729 |
| Ctrl 4 | F | 72 | None | Colon ascendens carcinoma | Colon ascendens | 1.0737 | 1.0338 |
| Ctrl 5 | M | 76 | None | Colon ascendens carcinoma | Colon ascendens | 1.0084 | 1.1396 |
| Ctrl 6 | M | 72 | None | Rectal cancer | Colon descendens | 1.1629 | 1.2536 |
| Ctrl 7 | F | 61 | None | Carcinoma of rectosigmoidal transition | Colon descendens | 1.1048 | 1.0917 |
| Ctrl 8 | M | 91 | None | Colon ascendens carcinoma | Colon ascendens | 1.2847 | 0.8669 |
| UC 1 | M | 62 | None | Colitis-associated carcinoma, active UC | Colon ascendens | 0.6556 | 1.0374 |
| UC 2 | M | 54 | Budenoside, mesalazine | Active UC, neuroendocrine tumor | Rectum | 1.0147 | 1.0622 |
| UC 3 | M | 53 | Adalimumab, prednisolone, mesalazine | Active UC | Colon descendens | 0.8057 | 1.1579 |
| UC 4 | M | 53 | Infliximab, prednisolone | Active UC | Colon descendens | 0.5482 | 0.9525 |
| UC 5 | M | 41 | Vedolizumab | Active UC | Colon sigmoideum | 0.1410 | 0.0740 |
| UC 6 | M | 59 | Adalimumab, prednisolone | Chronic UC | Colon descendens | 2.1653 | 1.0526 |
| UC 7 | M | 55 | Mesalazine | Chronic UC Colitis-associated carcinoma | Colon descendens | 1.2074 | 1.2264 |
| UC 8 | F | 20 | None | Indeterminate colitis | Colon descendens | 0.7710 | 0.7946 |
| UC 9 | M | 60 | Prednisolone, mesalazine | Chronic UC | Colon descendens | 1.0324 | 0.9578 |
| UC 10 | F | 38 | None | Chronic UC Colitis-associated carcinoma Colon | Descendens | 0.8791 | 0.9460 |
| UC 11 | F | 60 | Infliximab | Vezolizumab | Chronic UC Colon descendens | 0.4683 | 1.0890 |
IEN, intraepithelial neoplasia. Pixel intensities of arpin and ArpC5 bands (normalized to their respective actin bands) from blots in Figure 4B are shown.